They are Professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel.
MacLaren works at the University of Oxford where he directs research into developing new clinical treatments for blindness using stem cells, gene therapy and electronic retinal implants.
Temple is the scientific director of the Neural Stem Cell Institute in New York, where she leads a team of 30 researchers, while Sahel is the chair of the ophthalmology department at the University of Pittsburgh.
ReNeuron chief executive Olav Hellebø said: "We are delighted to welcome these renowned experts to our scientific advisory board.
“They will provide invaluable insight and counsel across ReNeuron's therapeutic programmes as we progress our pioneering therapies towards commercialisation."